AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investmen
Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paedi
